IBDEI211 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33965,1,3,0)
 ;;=3^Kidney Transplant Status
 ;;^UTILITY(U,$J,358.3,33965,1,4,0)
 ;;=4^Z94.0
 ;;^UTILITY(U,$J,358.3,33965,2)
 ;;=^5063654
 ;;^UTILITY(U,$J,358.3,33966,0)
 ;;=Z48.22^^154^1718^1
 ;;^UTILITY(U,$J,358.3,33966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33966,1,3,0)
 ;;=3^Aftercare Following Kidney Transplant
 ;;^UTILITY(U,$J,358.3,33966,1,4,0)
 ;;=4^Z48.22
 ;;^UTILITY(U,$J,358.3,33966,2)
 ;;=^5063039
 ;;^UTILITY(U,$J,358.3,33967,0)
 ;;=Z52.4^^154^1718^2
 ;;^UTILITY(U,$J,358.3,33967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33967,1,3,0)
 ;;=3^Kidney Donor
 ;;^UTILITY(U,$J,358.3,33967,1,4,0)
 ;;=4^Z52.4
 ;;^UTILITY(U,$J,358.3,33967,2)
 ;;=^5063082
 ;;^UTILITY(U,$J,358.3,33968,0)
 ;;=D47.Z1^^154^1718^9
 ;;^UTILITY(U,$J,358.3,33968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33968,1,3,0)
 ;;=3^Post-Transplant Lymphoproliferative Disorder (PTLD)
 ;;^UTILITY(U,$J,358.3,33968,1,4,0)
 ;;=4^D47.Z1
 ;;^UTILITY(U,$J,358.3,33968,2)
 ;;=^5002261
 ;;^UTILITY(U,$J,358.3,33969,0)
 ;;=T86.10^^154^1718^4
 ;;^UTILITY(U,$J,358.3,33969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33969,1,3,0)
 ;;=3^Kidney Transplant Complication,Unspec
 ;;^UTILITY(U,$J,358.3,33969,1,4,0)
 ;;=4^T86.10
 ;;^UTILITY(U,$J,358.3,33969,2)
 ;;=^5055708
 ;;^UTILITY(U,$J,358.3,33970,0)
 ;;=N18.1^^154^1719^1
 ;;^UTILITY(U,$J,358.3,33970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33970,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,33970,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,33970,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,33971,0)
 ;;=N18.2^^154^1719^2
 ;;^UTILITY(U,$J,358.3,33971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33971,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,33971,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,33971,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,33972,0)
 ;;=N18.3^^154^1719^3
 ;;^UTILITY(U,$J,358.3,33972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33972,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3
 ;;^UTILITY(U,$J,358.3,33972,1,4,0)
 ;;=4^N18.3
 ;;^UTILITY(U,$J,358.3,33972,2)
 ;;=^5015604
 ;;^UTILITY(U,$J,358.3,33973,0)
 ;;=N18.4^^154^1719^4
 ;;^UTILITY(U,$J,358.3,33973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33973,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,33973,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,33973,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,33974,0)
 ;;=N18.5^^154^1719^5
 ;;^UTILITY(U,$J,358.3,33974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33974,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,33974,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,33974,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,33975,0)
 ;;=N18.9^^154^1719^6
 ;;^UTILITY(U,$J,358.3,33975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33975,1,3,0)
 ;;=3^Chr Kidney Disease,Unspec
 ;;^UTILITY(U,$J,358.3,33975,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,33975,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,33976,0)
 ;;=N18.6^^154^1719^7
 ;;^UTILITY(U,$J,358.3,33976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33976,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,33976,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,33976,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,33977,0)
 ;;=N10.^^154^1720^5
 ;;^UTILITY(U,$J,358.3,33977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33977,1,3,0)
 ;;=3^Acute Tubulo-Interstitial Nephritis
 ;;^UTILITY(U,$J,358.3,33977,1,4,0)
 ;;=4^N10.
 ;;^UTILITY(U,$J,358.3,33977,2)
 ;;=^5015570
 ;;^UTILITY(U,$J,358.3,33978,0)
 ;;=N17.1^^154^1720^1
 ;;^UTILITY(U,$J,358.3,33978,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33978,1,3,0)
 ;;=3^AKI w/ Acute Cortical Necrosis
